Methylation pattern of Caveolin-1 in prostate cancer as potential cfDNA biomarker

High prevalence and mortality of prostate cancer (PCa) are well known global health issues. Novel biomarkers for better identifying patients with PCa are the subject of extensive research. Prostate specific antigen (PSA) shows low specificity in screening and diagnostics, leading to unnecessary biop...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules & Biomedicine Vol. 23; no. 1; pp. 176 - 186
Main Authors Škara, Lucija, Vodopić, Tonći, Pezelj, Ivan, Abramovic, Irena, Vrhovec, Borna, Vrtarić, Alen, Sincic, Nino, Tomas, Davor, Bulimbašić, Stela, Kuliš, Tomislav, Ulamec, Monika
Format Journal Article
LanguageEnglish
Published Bosnia and Herzegovina Association of Basic Medical Sciences 01.02.2023
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
Subjects
biomarker
Biomarkers - metabolism
CAV1
Caveolin 1 - genetics
Caveolins
Cell-Free Nucleic Acids - metabolism
cfDNA methylation
Diagnosis
DNA
Genetic aspects
Health aspects
Humans
Male
Methylation
Prostate cancer
Prostatic Hyperplasia
Prostatic Neoplasms - diagnosis
Croatia
Online AccessGet full text

Cover

More Information
Summary:High prevalence and mortality of prostate cancer (PCa) are well known global health issues. Novel biomarkers for better identifying patients with PCa are the subject of extensive research. Prostate specific antigen (PSA) shows low specificity in screening and diagnostics, leading to unnecessary biopsies and health costs. Eighty patients with PCa and benign prostate hyperplasia (BPH) were included in the study. We analyzed CAV1 gene expression and methylation in tissue. CAV1 cfDNA methylation from blood and seminal plasma was accessed as a potential PCa biomarker. Although methylation in blood plasma did not differ between PCa and BPH patients, methylation in seminal plasma showed better PCa biomarker performances than tPSA (AUC 0.63 vs. AUC 0.52). Discrimination of BPH and Gleason grade group 1 PCa patients from patients with higher Gleason grade groups revealed very good performance as well (AUC 0.72). CAV1 methylation is useful biomarker with potential for further seminal plasma cfDNA research, but its diagnostic accuracy should be improved, as well as general knowledge about cfDNA in seminal plasma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1512-8601
2831-0896
2831-090X
1840-4812
2831-090X
DOI:10.17305/bjbms.2022.7497